DBV Technologies S.A.

DBV Technologies is a late-stage specialty biopharmaceutical company focused on developing a novel technology platform called Viaskin for immunotherapy. The company's therapeutic approach, epicutaneous immunotherapy (EPIT), delivers biologically active compounds to the immune system through intact skin using the Viaskin epicutaneous patch. This patch targets antigen-presenting immune cells in the skin, called Langerhans cells, which capture the antigen and migrate to the lymph nodes to activate the immune system without the antigen entering the bloodstream, thereby minimizing systemic exposure. DBV Technologies is advancing this technology to treat children with food allergies. Its most advanced product candidate is Viaskin® Peanut Patch, which has been evaluated as a potential therapy for children with peanut allergy in twelve completed clinical trials, including five Phase 2 trials and five completed Phase 3 trials. The company plans a Biologics License Application (BLA) submission in the first half of 2026 for Viaskin Peanut Patch as a potential treatment for children four to seven years old. Additionally, the company has an ongoing Phase 3 supplementary safety study of Viaskin Peanut patch in peanut-allergic toddlers ages one through three. Conditional on successful completion of this safety study, the company plans a BLA submission in the second half of 2026 for children ages one to three. DBV Technologies also has earlier-stage food allergy programs, including Viaskin Milk, and other autoimmune inflammatory diseases.